Role of sphingosine 1-phosphate in trafficking and mobilization of hematopoietic stem cells

Current Opinion in Hematology

Volumn 20, Issue 4, 2013, Pages 281-288

  Bendall, Linda J ^a   Basnett, Jordan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hematopoietic stem cells; Mobilization; Sphingosine 1 phosphate

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ACT 209905; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CHEMOATTRACTANT; CYM 5442; FINGOLIMOD; GSK 2018682; NIBR 0213; PLERIXAFOR; PONESIMOD; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VPC 01091; W 146;

CELL HOMING; CELL MIGRATION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STEM CELL MOBILIZATION;

BONE MARROW CELLS; CHEMOTACTIC FACTORS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYSOPHOSPHOLIPIDS; SPHINGOSINE;

EID: 84880206703     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283606090     Document Type: Review

References (68)

1. Jansen J, Hanks S, Thompson J, et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9:37-50.
2. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100:761-767.
3. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34Ã hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45:295-300.
4. Flomenberg N, Devine S, Dipersio J, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867-1874.
5. Devine S, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990-998.
6. Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40:185-192.
7. Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 2009; 16:35-40.
8. D'Souza A, Jaiyesimi I, Trainor L, et al. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008; 22:280-290.
9. Funakoshi Y, Nazneen A, Nakashima Y, et al. Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donor. Bone Marrow Transplant 2010; 45:1477-1478.
10. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012; 30:69-94.
11. Rivera J, Proia R, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8:753-763.
12. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009; 78:743-768.
13. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine- 1-phosphate. Trends Endocrinol Metab 2007; 18:300-307.
14. Rosen H,Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005; 5:560-570.
15. Peest U, Sensken S, André ani P, et al. S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 2008; 104:756-772.
16. Schwab S, Pereira J, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005; 309:1735-1739.
17. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316:295-298.
18. Fukuhara S, Simmons S, Kawamura S, et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 2012; 122:1416-1426.
19. Kimura T, Boehmler A, Seitz G, et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34Ã progenitor cells. Blood 2004; 103:4478-4486.
20. Whetton AD, Lu Y, Pierce A, et al. Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav. Blood 2003; 102:2798-2802.
21. Yanai N, Matsui N, Furusawa T, et al. Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers. Blood 2000; 96:139-144.
22. Ratajczak MZ, Lee H, Wysoczynski M, et al. Novel insight into stem cell mobilization: plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010; 24:976-985.
23. Watterson KR, Johnston E, Chalmers C, et al. Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase J Biol Chem 2002; 277:5767-5777.
24. Ryser MF, Ugarte F, Lehmann R, et al. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34Ã hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing. Mol Immunol 2008; 46:166-171.
25. Nakamura-Ishizu A, Suda T. Hematopoietic stem cell niche: an interplay among a repertoire of multiple functional niches. Biochim Biophys Acta 2013; 1830:2404-2409.
26. Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol 2012; 19:250-255.
27. Park D, Sykes DB, Scadden DT. The hematopoietic stem cell niche. Front Biosci 2012; 17:30-39.
28. Broxmeyer H, Orschell C, Clapp D, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201:1307-1318.
29. Foudi A, Jarrier P, Zhang Y, et al. Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood 2006; 107:2243-2251.
30. Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90:4779-4788.
31. Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114:1340-1343.
32. Massberg S, Schaerli P, Knezevic-Maramica I, et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007; 131:994-1008. Although this study is not recent, this is the report that initiated the research into the role of S1P in HSC mobilization.
33. Juarez JG, Harun N, Thien M, et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012; 119:707-716
34. Golan K, Vagima Y, Ludin A, et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 2012; 119:2478-2488. This is an extensive and complex study that examines the mechanisms underlying the role of S1P in HSC mobilization. It also describes a role for S1P in G-CSFinduced HSC mobilization.
35. Halin C, Scimone M, Bonasio R, et al. The S1P-analog FTY720 differentially modulates T cell homing via HEV: T cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer's patches. Blood 2005; 106:1314-1322.
36. Maeda Y, Seki N, Sato N, et al. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol 2010; 22:515-525.
37. Pereira JP, Cyster JG, Xu Y. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS One 2010; 5:e9277.
38. Allende ML, Tuymetova G, Lee BG, et al. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med 2010; 207:1113-1124.
39. Kim CH, Wu W, Wysoczynski M, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 2012; 26:106-116.
40. Ratajczak MZ, Kim C, Janowska-Wieczorek A, et al. The expanding family of bone marrow homing factors for hematopoietic stem cells: stromal derived factor 1 is not the only player in the game. Sci World J 2012; 2012: 758512.
41. Siehler S, Manning DR. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim Biophys Acta 2002; 1582:94-99.
42. Papayannopoulou T, Priestley GV, Bonig H, et al. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. Blood 2003; 101:4739-4747.
43. Levesque J, Takamatsu Y, Nilsson S, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98:1289-1297.
44. Levesque J, Hendy J, Winkler I, et al. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003; 31:109-117.
45. Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34Ã cell populations based on global gene and microRNA expression signatures. Blood 2009; 114:2530-2541.
46. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261:600-603.
47. Bonig H, Chudziak D, Priestley G, et al. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009; 37:402-415; e1.
48. Yamamoto Y, Yasumizu R, Amou Y, et al. Characterization of peripheral blood stem cells in mice. Blood 1996; 88:445-454.
49. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012; 20:230-238.
50. Ohtani O, Ohtani Y. Lymph circulation in the liver. Anat Rec (Hoboken) 2008; 291:643-652.
51. Mendt M, Cardier JE. Stromal-derived factor-1 and its receptor, CXCR4, are constitutively expressed by mouse liver sinusoidal endothelial cells: implications for the regulation of hematopoietic cell migration to the liver during extramedullary hematopoiesis. Stem Cells Dev 2012; 21:2142-2151.
52. Schroder M, Richter C, Juan MH, et al. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen. Mol Immunol 2011; 48:1139-1148.
53. Gonzalez-Cabrera PJ, Jo E, Sanna MG, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 2008; 74:1308-1318.
54. Pan S, Mi Y, Pally C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 2006; 13:1227-1234.
55. Oo ML, Chang SH, Thangada S, et al. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest 2011; 121:2290-2300.
56. Oliveira CC, Dos Santos EA, Nunes JH, et al. Stereoselective arylation of substituted cyclopentenes by substrate-directable Heck-Matsuda reactions: a concise total synthesis of the sphingosine 1-phosphate receptor (S1P(1)) agonist VPC01091. J Org Chem 2012; 77:8182-8190.
57. Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010; 53:4198-4211.
58. Quancard J, Bollbuck B, Janser P, et al. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol 2012; 19:1142-1151.
59. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005; 12:703-715.
60. Schmidt G, Reber S, Bolli M, et al. Practical and scalable synthesis of S1P1 receptor agonist ACT-209905. Org Process Res Dev 2012; 16:595-604.
61. Brinkmann V, DavisMD, HeiseCE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277:21453-21457.
62. Tarrason G, Auli M, Mustafa S, et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int Immunopharmacol 2011; 11:1773-1779.
63. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279:13839-13848.
64. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005; 6:1228-1235.
65. Weiss L, editor. Cell and tissue biology: a textbook of histology. 6th ed. Baltimore, MD: Urban Schwarzenberg; 1988.
66. Whetzel AM, Bolick DT, Srinivasan S, et al. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 2006; 99:731-739.
67. FDA approves the first oral drug for reducing multiple sclerosis relapses. Harv Womens Health Watch 2010; 18:5.
68. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13:1073-1083.